Cardio Diagnostics Holdings, Inc.

CDIO

Cardio Diagnostics Holdings, Inc.

CDIO

Insider Sentiment (TTM):

Last Purchase:2024-09-06Last Sale:-Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:213,940Shares Outstanding:2,840,778Institutional Ownership Pct.:7.53%

Earnings Market Reaction:

Filing Date:2026-05-15Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in In Vitro & In Vivo Diagnostic Substances

IDXX LNTH NEOG NTLA QDEL MYGN

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash	7	5	6	8	10	8	2	1	2	1	4	5
Accounts Receivable Net Current	0	0	0	0	0	0	0	0	0	0	0	0
Prepaid Expense And Other Assets Current	1	1	1	1	1	1	1	1	1	1	1	1
Assets Current	8	6	7	9	11	9	3	2	3	3	5	6
Assets Noncurrent
Property Plant And Equipment Net	1	1	1	1	1	1	1	1	1	1	0	0
Operating Lease Right Of Use Asset	0	0	0	0	0	0	0	1	1	1	1	1
Finite Lived Intangible Assets Net	-	-	-	-	0	0	0	0	0	0	0	0
Deposits Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Other Intangible Assets Net	1	1	1	1	1	1	1	1	1	1	0	0
Assets	10	8	9	10	12	11	4	4	4	4	6	7
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Accrued Liabilities Current	0	0	0	0	0	0	0	0	0	0	1	1
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	-
Convertible Notes Payable Current	-	-	-	-	-	-	-	-	-	-	1	1
Derivative Liabilities Current	-	-	-	-	-	-	-	-	-	-	1	2
Liabilities Current	0	1	0	0	1	1	0	0	1	1	3	-
Liabilities Noncurrent
Liabilities Noncurrent	0	0	0	0	0	0	0	1	1	1	1	-
Liabilities	1	1	1	1	1	1	1	1	1	2	4	4
Preferred Stock Value	-	-	-	-	-	-	-	-	-	-	0	0
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	40	36	36	36	36	32	25	23	22	17	15	14
Retained Earnings Accumulated Deficit	-31	-29	-28	-26	-24	-23	-21	-20	-19	-14	-13	-11
Stockholders Equity	9	7	8	10	11	10	4	3	3	3	2	3
Liabilities And Stockholders Equity	10	8	9	10	12	11	4	4	4	4	6	7
Preferred Stock Par Or Stated Value Per Share	0	0	0	1	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	100	100	100	100	100	100	100	100	100	100	100	100
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	-	0	0	0	0	0	0	-	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	-	300	300	300
Common Stock Shares Issued	3	-	4	3	3	46	30	23	-	21	13	11
Shares Outstanding	30	33	32	31	31	31	30	23	-	21	13	11

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	26.45%	28.39%	-	-	-	-	-	-	-	-	-	-
2025	19.12%	-5.00%	-3.00%	-7.78%	13.10%	0.42%	-2.41%	-24.06%	-59.63%	-27.14%	-32.86%	-32.50%
2024	-20.07%	-35.30%	-48.05%	-34.98%	-49.33%	-41.70%	78.57%	210.39%	42.53%	-7.95%	-57.95%	-63.90%
2023	-	-	-	-52.65%	-65.87%	-59.48%	21.43%	105.36%	91.96%	-50.36%	-50.65%	-56.83%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	15.76	9.79	17.39	23.55	19.49	13.92	8.51	5.69	3.78	3.29	1.53	-
Quick Ratio	14.41	8.46	15.98	21.59	17.94	12.42	6.47	3.50	2.31	1.53	1.23	-
Working Capital	7.25M	5.32M	6.53M	8.33M	9.99M	8.16M	2.32M	1.76M	1.90M	1.92M	1.57M	-
Leverage & Debt
Debt to Equity	0.07	0.11	0.08	0.07	0.08	0.11	0.22	0.30	0.43	0.51	1.61	-
Interest Coverage TTM	-489.95	-438.08	-418.09	-380.46	-333.36	-448.81	-75.18	-12.43	-5.62	-1.08	-1.22	-1.28
Debt Ratio	0.07	0.10	0.07	0.06	0.07	0.10	0.18	0.23	0.30	0.34	0.62	-
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.00	0.00	0.00
Days Sales Outstanding TTM	152.32	329.15	292.81	191.29	261.71	123.30	73.89	39.96	210.06	104.73	9.88	132.34
Receivables Turnover TTM	2.40	1.11	1.25	1.91	1.39	2.96	4.94	9.13	1.74	3.49	36.93	2.76
Per Share Metrics
Diluted EPS TTM	-2.34	-1.86	-1.86	-1.80	-1.74	-2.34	-2.53	-2.91	-9.83	-2.97	-3.54	-3.77
Free Cash Flow Per Share TTM	-2.17	-1.71	-1.69	-1.60	-1.59	-1.45	-1.85	-1.96	-5.00	-2.24	-2.72	-3.33
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	181.79%	199.84%	199.07%	184.01%	188.00%	153.43%	412.75%	1,832.64%	5,326.01%	39,062.24%	-	-
Operating Profit Margin TTM	-40,074.58%	-43,737.46%	-41,422.24%	-31,960.98%	-29,335.69%	-23,977.86%	-23,513.43%	-21,530.73%	-29,392.23%	-41,897.83%	-62,540.45%	-269,014.61%
Net Profit Margin TTM	-40,152.50%	-43,832.49%	-41,516.33%	-32,040.48%	-29,418.82%	-24,028.24%	-23,125.63%	-22,415.27%	-34,879.52%	-48,460.22%	-72,458.32%	-296,424.55%
Growth Metrics
Net Revenue Growth (1Y)	-16.77%	-57.51%	-55.78%	-50.16%	-39.68%	101.84%	176.09%	1,251.45%	2,717.51%	1,719.58%	-	-
Net Income Growth (1Y)	13.60%	-22.49%	-20.61%	-28.76%	-49.12%	0.08%	-11.88%	2.20%	127.69%	94.28%	384.38%	-
EPS Growth (1Y)	34.86%	-20.65%	-26.41%	-38.26%	-82.33%	-21.32%	-28.48%	-22.83%	3.13%	41.87%	303.71%	-
Valuation Metrics
P/E TTM	-0.83	-1.46	-2.15	-2.00	-5.70	-11.77	-2.64	-5.67	-4.33	-25.14	-2.88	-9.47
P/B TTM	0.62	1.36	1.73	1.29	2.93	10.32	5.91	16.18	16.43	71.18	11.79	27.94
P/S TTM	334.41	640.32	893.32	641.88	1,677.50	2,827.24	610.93	1,270.80	1,511.92	12,181.72	2,087.40	28,058.22
Market Cap	5.54M	9.49M	14.10M	12.52M	33.39M	98.64M	21.80M	49.74M	49.88M	210.57M	26.98M	81.26M
Enterprise Value	-1.54M	4.38M	7.74M	4.55M	23.70M	95.67M	19.82M	48.43M	48.32M	209.29M	24.32M	77.13M
Calculated Values
Free Cash Flow TTM	-6.15M	-5.99M	-5.95M	-5.57M	-5.36M	-5.21M	-6.03M	-5.91M	-5.85M	-6.30M	-7.20M	-7.57M
Net Debt	-7.08M	-5.11M	-6.36M	-7.97M	-9.69M	-2.97M	-1.98M	-1.31M	-1.56M	-1.28M	-2.66M	-4.13M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2024-09-06Purchase

Owner: Dogan, Meeshanthini

Title: Chief Executive Officer

Shares: 68,965

Price/Share: $0.29

Value: $19,999.85

Shares Owned: 1,655,429

Relationship: Director,Officer

Ownership: Direct

2024-09-06Purchase

Owner: Dogan, Meeshanthini

Title: Chief Executive Officer

Shares: 68,965

Price/Share: $0.29

Value: $19,999.85

Shares Owned: 1,683,867

Relationship: Director,Officer

Ownership: Direct

2024-09-06Purchase

Owner: Philibert, Robert

Title: Chief Medical Officer

Shares: 34,075

Price/Share: $0.29

Value: $9,881.75

Shares Owned: 1,683,867

Relationship: Director,Officer

Ownership: Indirect

2024-09-06Purchase

Owner: Dogan, Timur

Title: Chief Technology Officer

Shares: 68,965

Price/Share: $0.29

Value: $19,999.85

Shares Owned: 197,310

Relationship: Officer

Ownership: Direct

2024-09-06Purchase

Owner: Dogan, Timur

Title: Chief Technology Officer

Shares: 68,965

Price/Share: $0.29

Value: $19,999.85

Shares Owned: 197,310

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2024-09-06	Dogan, Meeshanthini	Director,Officer	Chief Executive Officer	Direct	Purchase	68,965	0.29	$19,999.85	1,655,429	4/A
2024-09-06	Dogan, Meeshanthini	Director,Officer	Chief Executive Officer	Direct	Purchase	68,965	0.29	$19,999.85	1,683,867	4
2024-09-06	Philibert, Robert	Director,Officer	Chief Medical Officer	Indirect	Purchase	34,075	0.29	$9,881.75	1,683,867	4
2024-09-06	Dogan, Timur	Officer	Chief Technology Officer	Direct	Purchase	68,965	0.29	$19,999.85	197,310	4/A
2024-09-06	Dogan, Timur	Officer	Chief Technology Officer	Direct	Purchase	68,965	0.29	$19,999.85	197,310	4/A
2024-09-06	Dogan, Meeshanthini	Officer	Chief Technology Officer	Direct	Purchase	68,965	0.29	$19,999.85	197,310	4
2023-08-31	Dogan, Timur	Officer	Chief Technology Officer	Direct	Purchase	16,481	0.55	$9,064.55	128,345	4
2023-08-31	Dogan, Meeshanthini	Director,Officer,TenPercentOwner	Chief Executive Officer	Indirect	Purchase	16,481	0.55	$9,064.55	128,345	4
2023-08-28	Philibert, Robert	Director,Officer,TenPercentOwner	Chief Medical Officer	Indirect	Purchase	18,000	0.58	$10,440.00	1,649,792	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

7.53%

Inst. Shares: 213,940

Shares Outstanding: 2,840,778

2025-12-31

7.40%

Inst. Shares: 259,040

Shares Outstanding: 3,502,834

2025-09-30

6.54%

Inst. Shares: 229,952

Shares Outstanding: 3,515,800

2025-06-30

4.87%

Inst. Shares: 169,318

Shares Outstanding: 3,478,090

2025-03-31

147.61%

Inst. Shares: 4,977,934

Shares Outstanding: 3,372,288

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	213,940	2,840,778	7.53%
2025-12-31	259,040	3,502,834	7.40%
2025-09-30	229,952	3,515,800	6.54%
2025-06-30	169,318	3,478,090	4.87%
2025-03-31	4,977,934	3,372,288	147.61%
2024-12-31	4,824,278	3,585,696	134.54%
2024-09-30	3,333,562	3,259,048	102.29%
2024-06-30	3,622,290	3,014,348	120.17%
2024-03-31	3,244,846	2,810,296	115.46%
2023-12-31	3,312,228	2,818,918	117.50%
2023-09-30	3,373,624	2,645,268	127.53%
2023-06-30	2,993,648	2,276,096	131.53%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Cardio Diagnostics Holdings, Inc. (CDIO) — SEC Financial Statements & Analysis

Cardio Diagnostics Holdings, Inc. (CDIO) is a in vitro & in vivo diagnostic substances company, incorporated in DE. Cardio Diagnostics Holdings, Inc. trades on Nasdaq as: CDIO, CDIOW. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Cardio Diagnostics Holdings, Inc. reported a -16.77% year-over-year revenue growth, a Gross Profit Margin of 181.79% (TTM), a Debt-to-Equity ratio of 0.07x, a Price-to-Sales (P/S) ratio of 334.41x (TTM), a Price-to-Book (P/B) ratio of 0.62 (TTM), at a market cap of $5.54M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -16.77%
Gross Profit Margin TTM: 181.79%
Debt To Equity: 0.07x
P/S TTM: 334.41x
P/B TTM: 0.62
Market Cap: $5.54M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Cardio Diagnostics Holdings, Inc. in?

Cardio Diagnostics Holdings, Inc. (CDIO) operates in the In Vitro & In Vivo Diagnostic Substances industry.

What is CDIO's market cap?

Cardio Diagnostics Holdings, Inc. (CDIO) has a market capitalization of $5.54M as of 2026-03-31.

What exchange does CDIO trade on?

Cardio Diagnostics Holdings, Inc. (CDIO) trades on the Nasdaq.

Where is Cardio Diagnostics Holdings, Inc. incorporated?

Cardio Diagnostics Holdings, Inc. is incorporated in DE.

Cardio Diagnostics Holdings, Inc. (CDIO) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.